Reading ZYME? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZYME free→
Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Watch· this week
$22.88-0.37%
Close 2026-06-12 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 153% below where it trades (it looks expensive on this basis); the read is rich. If ZYME cuts guidance on the next call, that's a meaningful negative. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $1.68B
- Employees
- —
- IPO date
- 2022-11-08
- Next earnings
- 2026-08-06
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $22.88. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$11.66consensus
Range $9.80 – $13.53
vs price: +96% above
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-year—
—consensus
Range — – —
vs price: —
Method agreement —
Embeds projected growth. Leans optimistic by design. Upside context.
5-year—
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Optionality premiumlow confidence
At $23, ZYME's earnings are too small for P/E to mean much; on sales it trades at 35× p/s (3.7× the 9× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $8.88 fair value covers only the as-is business, low confidence. Analysts: $28–$48. Not investment advice.
Multiple (P/S)
35.2x
peer 9.4x · own history —
Premium
3.7x peer
Growth the price needs
158%
our forecast —
Our fair value
$8.88
range $7.51 – $10.25
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced in
The market is pricing in roughly 158% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Elevated fragilityrisk posture, not a price call
Flags: expensive valuation, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
2nd pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.73x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
volatileEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
BearishEPS revised -39.6% / 30d, n=9for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.30 → $-0.42 (-39.6% / 30d). 0 raised, 4 cut, 9 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
Price target activity
2 PT revisions / 30d. Avg target 53.9% above current price.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- neutral
- Earnings discipline
- weak
- Margin discipline
- neutral
- Balance sheet
- weak
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-15
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$193.
How much price usually moves either way.
On a bad day, this stock has moved -$412.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,028.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- Either wayMedium confidenceMonthsactive 4d
Watch for Q2 earnings report on August 6, 2026
Why it matters: This report will show if Zymeworks can improve its financial situation. Investors will look for signs of recovery or continued losses.
What confirms / what disproves
Confirms one read:The earnings report shows revenue growth. It also shows smaller losses than before.
Confirms the other:The earnings report shows bigger losses. Revenue has not changed compared to before.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ZYME yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting ZYME and other Healthcare names. Worth watching these names for early signals.
- If ZYME raises forward guidance on the next earnings call (currently REAFFIRMED as of 2026-05-07), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If ZYME cuts guidance on the next call (currently REAFFIRMED as of 2026-05-07), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping ZYME and other Healthcare names could fade. Watch these names for early warning.
- If ZYME misses again next quarter like this past one (a very large miss off a near-zero prior-year base on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-071mo agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 7, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”).
Earnings preannouncementnegative
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+1.6 vs last weeklatest as of 2026-06-15
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.